Fenebrutinib, Genentech’s investigational BTK inhibitor, was found to significantly reduce relapse rates compared with the approved therapy Aubagio (teriflunomide) in two Phase 3 clinical trials involving people with relapsing forms of multiple sclerosis (MS). Positive top-line results from one of those trials, FENhance 2 (NCT04586023), were announced late last year. Now, Genentech has reported that…
I don’t have to be an Olympic medalist to achieve remarkable things
Growing up, athleticism was part of my identity. To a degree, I measured myself by what I was physically capable of doing. I was constantly driven to test my limits, always aiming for higher, stronger, and more daring. I’m still in awe at what the human body is capable of. This February, I watched the…
How MS Australia’s 2026 Main Grants Round is advancing MS research
The post How MS Australia’s 2026 Main Grants Round is advancing MS research appeared first on MS Australia. Source: www.msaustralia.org.au
Scientists take major step toward changing the course of multiple sclerosis
The post Scientists take major step toward changing the course of multiple sclerosis appeared first on MS Australia. Source: www.msaustralia.org.au
New study links specific MRI lesion pattern to MS risk before symptoms
A specific pattern of damage seen on MRI scans, called a paramagnetic rim lesion, is associated with a higher risk of developing overt multiple sclerosis (MS) in people who have MS-like brain lesions but no symptoms, according to a new study. This condition is known as radiologically isolated syndrome (RIS), which refers to people who…
With MS, parenting a teenager can get a little bloody — for dad
In recognition of Multiple Sclerosis Awareness Month in March, the MS Awareness Month campaign features a series of stories highlighting the real-life experiences of people affected by MS, written in their own words. Follow us on Facebook, Instagram, X, and Pinterest for more stories like this, using the hashtag #MSAwarenessMonth, or read the full series….
Survey results: Psychological impact of Discontinuing DMTs
Tweet We had 21 replies from the post exploring this (How to stop treatment – The MS-Blog) and below is what you guys had to say. Note this is a very small sample size and isn’t generalisable to everyone who has stopped treatment. Figure 1: Survey results for the question Psychological Impact (please indicate how…
Does Fingo stop Drinking…Can MSers do the human Experiment
Tweet When we do animal experients the concept of 3Rs (Replacement, Reduction are relevant here) should come into the equation and so this paper grabbed my attention as it suggests that drugs like fingolimod, ozanimod and by inference ponesimod and siponimod may affect drinking alcohol….Here they do experiments in mice. It is interesting that the…
Foralumab reduces microglial activity, inflammation in nonactive SPMS
Treatment with the experimental nasal spray therapy foralumab reduced microglial activity in people with nonactive secondary progressive multiple sclerosis (SPMS), according to new data from an expanded access program. Microglia, the brain’s resident immune cells, are believed to contribute to the chronic inflammatory processes that drive gradual disease progression in the absence of relapses. These…
Your MS, Your Voice: The Power of Self-Advocacy — MS Awareness Month Highlights & Resources
MSAA proudly recognizes March as Multiple Sclerosis Awareness Month and is pleased to present the MS community with helpful and encouraging resources and programs throughout the month. Our MS Awareness Month theme in 2026 – Your MS, Your Voice: The … Continue reading → Source: blog.mymsaa.org